Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
…, J North, D Christie, NA Spry, KH Tai, C Wynne… - The lancet …, 2011 - thelancet.com
Background The TROG 96.01 trial assessed whether 3-month and 6-month short-term
neoadjuvant androgen deprivation therapy (NADT) decreases clinical progression and mortality …
neoadjuvant androgen deprivation therapy (NADT) decreases clinical progression and mortality …
[PDF][PDF] Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
…, MC Gittelman, DL Bilhartz, C Wynne… - Journal of Clinical …, 2005 - academia.edu
… Bilhartz, Chris Wynne, Robin Murray, Norman R. Zinner, Claude Schulman, Ronald Linnartz,
Ming Zheng, Carsten Goessl, Yong-Jiang Hei, Eric J. Small, Richard Cook, and Celestia S. …
Ming Zheng, Carsten Goessl, Yong-Jiang Hei, Eric J. Small, Richard Cook, and Celestia S. …
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised …
…, D Christie, NA Spry, KH Tai, C Wynne… - The lancet …, 2005 - thelancet.com
Background Androgen deprivation is an established treatment regimen for disseminated
prostate cancer; however, its role in patients with localised cancer is less clear. We did a large …
prostate cancer; however, its role in patients with localised cancer is less clear. We did a large …
Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2‐positive breast …
C Wynne, V Harvey, C Schwabe… - The Journal of …, 2013 - Wiley Online Library
Trastuzumab is a key component of treatment for human epidermal growth factor receptor 2 (HER2)–positive
breast cancer in both the early and metastatic settings. It is administered …
breast cancer in both the early and metastatic settings. It is administered …
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial
…, J North, M Poulsen, NA Spry, KH Tai, C Wynne… - Radiotherapy and …, 2009 - Elsevier
PURPOSE: We sought to categorize longitudinal radiation-induced rectal toxicity data
obtained from men participating in a randomised controlled trial for locally advanced prostate …
obtained from men participating in a randomised controlled trial for locally advanced prostate …
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
…, V Raghavan, U Osaghae, C Wynne… - Clinical and …, 2023 - Wiley Online Library
Inappropriate and chronic activation of the cytosolic NOD‐, LRR‐, and pyrin domain‐containing
3 (NLRP3) inflammasome, a key component of innate immunity, likely underlies several …
3 (NLRP3) inflammasome, a key component of innate immunity, likely underlies several …
Development of a subcutaneous fixed‐dose combination of pertuzumab and trastuzumab: results from the phase Ib dose‐finding study
WP Kirschbrown, C Wynne, M Kågedal… - The Journal of …, 2019 - Wiley Online Library
Adding pertuzumab to trastuzumab (both monoclonal antibodies targeting human epidermal
growth factor receptor 2 [HER2]) has proven survival benefits when combined with …
growth factor receptor 2 [HER2]) has proven survival benefits when combined with …
Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation
…, J North, M Poulsen, NA Spry, KH Tai, C Wynne… - Radiotherapy and …, 2005 - Elsevier
BACKGROUND AND PURPOSE: To identify contributing factors to delayed rectal and
urinary symptoms in a randomised trial comparing different durations of maximal androgen …
urinary symptoms in a randomised trial comparing different durations of maximal androgen …
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized …
…, J Monnet, AS Racault, C Wynne - Expert Review of …, 2022 - Taylor & Francis
Background Tocilizumab is a recombinant humanized monoclonal immunoglobulin G1
antibody against the interleukin-6 receptor (IL-6 R). MSB11456 is a proposed tocilizumab …
antibody against the interleukin-6 receptor (IL-6 R). MSB11456 is a proposed tocilizumab …
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer
…, D Christie, NA Spry, KH Tai, C Wynne… - Radiotherapy and …, 2003 - Elsevier
Purpose: To determine the acceptability of short term neo-adjuvant maximal androgen
deprivation (MAD) to patients treated with external beam radiation for locally advanced prostate …
deprivation (MAD) to patients treated with external beam radiation for locally advanced prostate …
